GPC3靶向免疫PET成像肝细胞癌的转化研究
本研究开发了新型GPC3靶向免疫PET示踪剂[68Ga]Ga-aGPC3-Fab,在临床前模型中验证其靶向能力,并在5例疑似或确诊肝细胞癌患者中开展首次人体概念验证评估,结果显示该示踪剂安全性良好,能清晰检出肝内约1厘米的转移灶,包括MRI漏诊病灶。
要点
- 5例患者均耐受[68Ga]Ga-aGPC3-Fab PET检查,无不良反应。
- 该示踪剂可高对比度检出肝内约1厘米转移灶,含MRI漏诊病灶。
- 临床前显示[68Ga]Ga-aGPC3-Fab对GPC3阳性细胞有强亲和力和有效内化。
核心结论
- [68Ga]Ga-aGPC3-Fab安全性良好,可有效显示GPC3阳性病灶,有望作为常规影像的补充手段提高HCC诊断准确性。
研究设计与样本
- 临床前研究:体外实验、小动物PET/CT及离体生物分布实验评估GPC3靶向能力。
- 临床研究:5例影像学疑似或确诊HCC患者入组试点临床研究,接受[68Ga]Ga-aGPC3-Fab PET显像,定量分析肿瘤与非肿瘤组织摄取。
主要发现
- [68Ga]Ga-aGPC3-Fab放射化学纯度高,在GPC3阳性细胞中显示强亲和力和有效内化。
- 在皮下和原位GPC3阳性HCC小鼠模型中实现清晰肿瘤显像。
- 5例患者均耐受PET检查,无不良反应。
- [68Ga]Ga-aGPC3-Fab成功检出肝内约1厘米转移灶,成像对比度高,包括MRI漏诊病灶。
临床怎么用
- [68Ga]Ga-aGPC3-Fab PET可作为常规影像的补充,用于无创可视化GPC3表达并辅助HCC诊断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Accurate diagnosis of hepatocellular carcinoma (HCC) remains a clinical challenge. Glypican-3 (GPC3) is highly expressed in HCC but not in normal liver tissue, making it a promising target for PET-based molecular imaging, which may complement existing approaches for HCC diagnosis. In this study, we developed a new GPC3-targeted immunoPET radiotracer for noninvasive visualization of GPC3 expression and conducted a first-in-human, proof-of-concept evaluation in patients with HCC to assess its clinical feasibility. METHODS: An anti-GPC3 antigen-binding fragment (Fab) was generated under Good Manufacturing Practice conditions and labeled with Gallium-68 (68Ga) to obtain [68Ga]Ga-aGPC3-Fab. In vitro assays, small-animal PET/CT scans, and ex vivo biodistribution experiments were conducted to examine its GPC3 targeting ability. Five patients with radiologically suspected or diagnosed HCC were enrolled in a pilot clinical study and underwent [68Ga]Ga-aGPC3-Fab PET imaging. Radiotracer uptake in tumor and non-tumor tissues was quantitatively analyzed. RESULTS: [68Ga]Ga-aGPC3-Fab was synthesized with high radiochemical purity and demonstrated strong affinity and efficient internalization in GPC3-positive cells. It enabled clear tumor visualization in both subcutaneous and orthotopic GPC3-positive HCC mouse models. All five patients tolerated the PET procedure well, with no adverse effects. [68Ga]Ga-aGPC3-Fab successfully detected intrahepatic metastases approximately 1 cm in diameter with high imaging contrast, including lesions that missed on magnetic resonance imaging. CONCLUSION: [68Ga]Ga-aGPC3-Fab demonstrated a favorable safety profile and enabled effective visualization of GPC3-positive lesions. It may serve as a complementary approach to conventional imaging to improve the diagnostic accuracy of HCC. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT06383520. Registered on April 25, 2024 ( https://clinicaltrials.gov/study/NCT06383520 ).
引用
- Lin Z, Hu W, Li M, et al. Glypican-3-targeted immunoPET imaging of hepatocellular carcinoma: a translational study. Eur J Nucl Med Mol Imaging. 2026. PMID: 41688850. doi:10.1007/s00259-025-07739-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。